Table 3. Changes in sitting systolic and diastolic BP after add-on treatment with α1-blockers in stage 1 and stage 2 hypertensive patients .
| Stage 1 hypertension at baseline | Valsartan + Bunazosin (N = 25) | Valsartan + Doxazosin (N = 21) | p value (between groups) |
| Systolic BP (mmHg) | |||
| Start of add-on therapy | 140.6 ± 5.3 | 138.6 ± 11.1 | 0.894 |
| Study end | 128.4 ± 12.0 | 126.3 ± 13.8 | 0.433 |
| Change | -12.2 ± 9.2 | -12.3 ± 13.8 | 0.825 |
| p value (within group) | < 0.001 | < 0.001 | |
| Diastolic BP (mmHg) | |||
| Start of add-on therapy | 91.7 ± 4.8 | 89.2 ± 6.8 | 0.204 |
| Study end | 82.3 ± 7.0 | 79.5 ± 8.6 | 0.255 |
| Change | -9.4 ± 5.2 | -9.7 ± 5.6 | 0.947 |
| Percentage change | -10.1 ± 5.6% | -10.1 ± 5.9% | 0.802 |
| p value (within group) | < 0.001 | < 0.001 | |
| Stage 2 hypertension at baseline | Valsartan + Bunazosin (N = 22) | Valsartan + Doxazosin (N = 25) | p value (between groups) |
| Systolic BP (mmHg) | |||
| Start of add-on therapy | 145.9 ± 10.4 | 139.9 ± 12.3 | 0.098 |
| Study end | 131.6 ± 9.3 | 133.3 ± 18.2 | 0.693 |
| Change | -14.4 ± 8.1 | -6.6 ± 13.8 | 0.015 |
| Percentage change | -9.7± 5.3% | -4.7 ± 9.5% | 0.020 |
| p value (within group) | < 0.001 | < 0.001 | |
| Diastolic BP (mmHg) | |||
| Start of add-on therapy | 94.6 ± 8.8 | 93.4 ± 6.9 | 0.536 |
| Study end | 85.5 ± 7.8 | 85.8 ± 10.7 | 0.796 |
| Change | -9.9 ± 5.0 | -7.6 ± 7.4 | 0.798 |
| Percentage change | -9.5 ± 4.9% | -8.2 ± 8.0% | 0.840 |
| p value (within group) | < 0.001 | < 0.001 |
BP, blood pressure.